This website uses own and third-party cookies to enhance the user's experience.
By clicking "Accept" on this banner or using our site, you consent to the use of cookies.
For settings and more information about cookies, view our
Cookie Policy.

Anjay Rastogi, MD PhD is Professor and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, Los Angeles, California. Dr. Rastogi is board certified in Nephrology and has a doctoral degree (PhD) in Pharmacology. He did his Internal Medicine residency and Nephrology fellowship at UCLA and completed his graduate training under the mentorship of Nobel Laureate Professor, Louis Ignarro also at UCLA. He is heavily involved in research and serves as the Director of Nephrology Clinical Research Program, Medical Director of the ESRD | Dialysis Program, and Living Kidney Donor Program. He founded the CORE Kidney Program and the Bruin Beans Health Club at UCLA. Dr. Rastogi received an award for the UCLA Exceptional MD of the Year Award in 2014 for his demonstration of the UCLA values of Compassion, Respect, Excellence, Discovery, Integrity, and Teamwork. Dr. Rastogi’s research interests include, Adult PKD, Fabry's Disease, Alport Syndrome and Diabetic Kidney Disease.

Dr. Rastogi is also the director of the CORE PKD Center at UCLA. The UCLA Polycystic Kidney Disease (PKD) Program is dedicated to providing the highest quality of patient care, performing cutting-edge research, and educating patients and healthcare professionals about the latest advances. UCLA offers comprehensive care for PKD for both ADPKD and autosomal recessive polycystic kidney disease (ARPKD) through a team approach that includes collaboration among specialists in nephrology, urology, radiology, transplant, dialysis, hepatology, neurology, cardiology, dermatology, genetics, OB/GYN, pain, infectious disease, nutrition, social work, patient advocacy, psychiatry, and pediatrics. UCLA is currently following over 580 ADPKD patients.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and more recently to treat acute kidney injury due to coronavirus infection. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Additional information on XORTX Therapeutics is available at www.xortx.com.

The CSE has neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, beliefs or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs and expectations will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements. The Company assumes no obligations to update any forward looking statements, whether as a result of new information, future events or otherwise.

About BiotechgateThe Canadian Life Sciences Database is a product of Venture Valuation and part of the global Life Sciences lead generation and intelligence platform Biotechgate. Our mission is to provide up-to-date company and business information of the Biotech, Pharma and Medtech sectors to professionals everywhere, in order to support them in identifying the most appropriate business partners, customers and suppliers.